Li Jianwen, Wang Weining
Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Department of Urology, Tsinghua University Yuquan Hospital, Beijing, China.
Br J Hosp Med (Lond). 2025 Jun 25;86(6):1-12. doi: 10.12968/hmed.2024.0881. Epub 2025 Jun 15.
Prostate cancer is a prevalent malignancy among men that frequently progresses to bone metastasis, significantly affecting prognosis and quality of life. Serum biomarkers such as miR-141-3p, fibrinogen (FIB), and prostate-specific antigen (PSA) are emerging as promising tools for early detection and personalised interventions for bone metastasis. This study investigated their predictive value for bone metastasis in prostate cancer. Conducted from March 2018 to March 2023, this study included 100 prostate cancer patients monitored over time. All participants underwent radionuclide bone imaging combined with positron emission tomography-computed tomography (PET-CT). Patients who developed bone metastasis (32 cases) were classified as the metastasis group, while those without (68 cases) were categorised as the non-metastasis group. Additionally, a control group of 50 healthy volunteers was established for comparison. A retrospective analysis assessed serum miR-141-3p, FIB, and PSA levels across the three groups. Clinical data were analysed to identify factors influencing bone metastasis using univariate and multivariate analyses, after which a prediction model was created to evaluate its prognostic value. Serum levels of miR-141-3p, FIB, and PSA were significantly different among the three groups, with the highest levels in the metastasis group, followed by the non-metastasis group, and the lowest in the control group ( < 0.05). Both univariate and multivariate analyses confirmed that these serum biomarkers significantly influenced the occurrence of bone metastasis. The combined predictive model demonstrated high clinical value for assessing the risk of bone metastasis in prostate cancer, with an area under the curve (AUC) of 0.923 (95% confidence interval [CI]: 0.868-0.979, < 0.05). Serum levels of miR-141-3p, FIB, and PSA are elevated in prostate cancer patients, particularly those with bone metastasis. The predictive model utilising these biomarkers effectively forecasts the likelihood of bone metastasis.
前列腺癌是男性中一种常见的恶性肿瘤，常进展为骨转移，严重影响预后和生活质量。血清生物标志物如miR-141-3p、纤维蛋白原（FIB）和前列腺特异性抗原（PSA）正成为早期检测和骨转移个性化干预的有前景的工具。本研究调查了它们对前列腺癌骨转移的预测价值。本研究于2018年3月至2023年3月进行，纳入了100例随时间监测的前列腺癌患者。所有参与者均接受了放射性核素骨显像联合正电子发射断层扫描-计算机断层扫描（PET-CT）。发生骨转移的患者（32例）被分类为转移组，未发生骨转移的患者（68例）被分类为非转移组。此外，设立了50名健康志愿者作为对照组进行比较。通过回顾性分析评估三组患者血清miR-141-¾p、FIB和PSA水平。采用单因素和多因素分析对临床资料进行分析，以确定影响骨转移的因素，之后建立预测模型以评估其预后价值。三组患者血清miR-141-3p、FIB和PSA水平差异有统计学意义，转移组最高，其次是非转移组，对照组最低（<0.05）。单因素和多因素分析均证实这些血清生物标志物显著影响骨转移的发生。联合预测模型在评估前列腺癌骨转移风险方面具有较高的临床价值，曲线下面积（AUC）为0.923（95%置信区间[CI]：0.868-0.979，<0.05）。前列腺癌患者，尤其是发生骨转移的患者，血清miR-141-3p、FIB和PSA水平升高。利用这些生物标志物的预测模型可有效预测骨转移的可能性。
